Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of ACI-7104.056 in early Parkinson's disease
2022-500292-31-00Phase 2Authorised
- Sponsor
- AC Immune SA
- Start
- Nov 2022
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing ACI-7104.056 with Placebo (2 arms). Primary endpoints: Safety and tolerability and Immunogenicity. Planned start Nov 2022; status: authorised.
02
Drugs
AFFITOPE PD03A
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2022-500292-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500292-31-00.